6:49 PM
 | 
May 21, 2010
 |  BC Extra  |  Clinical News

Roche reports T-DM1 data

Roche (SIX:ROG; OTCQX:RHHBY) said trastuzumab-DM1 ( T-DM1) plus pertuzumab produced two partial responses and seven unconfirmed partial responses in a Phase Ib/II trial...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >